ERBB2 and breast cancer: The literature describes unfavorable clinicopathologic features in young women with BC, such as less screen detection, higher tumor grade, more HER2 positive disease, less positive hormone receptor status, and more triple-negative subtype, increasing the prevalence of the advanced-stage disease.28